Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2015-07-30 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2015 (H1 2015). It contains detailed financial statements (Revenues, Gross Profit, Operating Costs, Net Result), a management discussion and analysis of the financial position, operational highlights, and a formal statement from the Board of Management. It is not merely an announcement of a report, but the report itself, containing substantive financial data and analysis for an interim period. H1 2015
2015-07-30 English
Pharming Reports on Financial Results First Half Year 2015
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2015 (H1 2015). It contains detailed financial statements, including a balance sheet summary, income statement highlights, and management's discussion and analysis of the results. It is not merely an announcement of a report, as it provides the actual financial data and operational highlights for the period. Therefore, it fits the definition of an Interim/Quarterly Report (IR). H1 2015
2015-07-30 English
HAEi Global Access Program for RUCONEST® Now Live
Regulatory Filings Classification · 95% confidence The document is a press release dated July 21, 2015, announcing the launch of the 'HAEi Global Access Program for RUCONEST®' through a collaboration between Pharming Group N.V. and Clinigen Group plc. It details the purpose of the program (providing access to a drug where it is not commercially available) and includes background information on the drug (RUCONEST), the disease (HAE), and the involved companies. This type of announcement, which communicates a specific business development, partnership, or operational update, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to financial results, but since it is a specific operational/access announcement without explicit quarterly financial highlights, RNS is the most appropriate general regulatory category for non-standard announcements. Given the options, it is a specific corporate announcement that doesn't fit the definitions for 10-K, IR, ER, or CT. It is not a report itself, but an announcement of an operational program. RNS serves as the best fit for general regulatory/corporate news releases.
2015-07-21 English
PHARMING ANNOUNCES US$17 MILLION (€15.6 MILLION) STRAIGHT DEBT FINANCING
Capital/Financing Update Classification · 99% confidence The document is an announcement titled "PHARMING ANNOUNCES US$17 MILLION (€15.6 MILLION) STRAIGHT DEBT FINANCING". It details the terms of a secured senior debt funding agreement, including principal amounts, interest rates, warrant coverage, and repayment schedules. This clearly falls under the category of updates on company fundraising or financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure changes.
2015-07-20 English
Pharming Announces Interim Results From the Ongoing Phase II Pediatric Clinical Trial of RUCONEST
Earnings Release Classification · 95% confidence The document is titled 'SNTS - Press Release re C.E. Unterberg Investor Conference' and contains detailed announcements about clinical trial results (Phase II pediatric trial of RUCONEST) and presentations at a scientific workshop (9th C1- Inhibitor Deficiency Workshop). It is a formal communication from the company (Pharming Group NV) detailing scientific and clinical progress, which aligns closely with an Investor Presentation (IP) or a general announcement. However, it is structured as a press release announcing data presented at a conference, rather than a formal regulatory filing (like 10-K or IR) or a standard earnings release (ER). Since it focuses on presenting scientific data and clinical updates to investors/the public, 'Investor Presentation' (IP) is the most fitting category, as these often include detailed scientific updates that might otherwise be in a presentation format, even if delivered via a press release. It is not a full Annual Report (10-K), an Interim Report (IR), or a simple Earnings Release (ER) which usually focuses only on key financial metrics. It is also not a Report Publication Announcement (RPA) because it contains substantive data, not just a notice that a report is available. H1 2015
2015-06-01 English
Pharming and Cytobioteck Announce Distribution Agreement for Ruconest
Environmental & Social Information Classification · 99% confidence The document is a press release dated May 25, 2015, announcing an exclusive distribution agreement between Pharming Group NV and Cytobioteck for the drug RUCONEST in Colombia and Venezuela. This type of announcement, detailing a business partnership, distribution rights, or strategic alliance, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or shareholder event categories (like AGM-R, DEF 14A). It is a general corporate announcement regarding business operations and strategy. Since it is not a report itself, nor a specific filing like a Director's Dealing or Capital Change, the most appropriate general category for significant corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which often serves as a catch-all for material press releases not covered by other specific codes.
2015-05-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.